An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)
作者:Peng Zhang、Deyong Ye、Yong Chu
DOI:10.1016/j.tetlet.2016.07.012
日期:2016.8
A practical and efficient method for the preparation of 1,5-benzothiazepinone derivatives in good yields has been developed using tetrabutylammonium fluoride (TBAF) as a catalyst. This study not only expands the previous work on the substrate scope and also provides more understanding of the chemistry of such drug scaffolds.
Lancelot, Jean-Charles; Letois, Bertrand; Saturnino, Carmela, Organic Preparations and Procedures International, 1992, vol. 24, # 2, p. 204 - 208
作者:Lancelot, Jean-Charles、Letois, Bertrand、Saturnino, Carmela、Caprariis, Paolo De、Robba, Max
DOI:——
日期:——
English, Robin B.; Kaye, Perry T.; Mphahlele, M. Jack, Journal of Chemical Research, Miniprint, 1995, # 10, p. 2319 - 2336
作者:English, Robin B.、Kaye, Perry T.、Mphahlele, M. Jack、Whittal, Rory D.
DOI:——
日期:——
Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β)
作者:Peng Zhang、Hai-Rong Hu、Shi-Hui Bian、Zhao-Hui Huang、Yong Chu、De-Yong Ye
DOI:10.1016/j.ejmech.2012.09.021
日期:2013.3
Glycogen synthase kinase-3 beta (GSK-3 beta) plays a key role in type II diabetes and Alzheimer's diseases, to which non-ATP competitive inhibitors represent an effectively therapeutical approach due to their good specificity. Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3 beta have been designed and synthesized. The in vitro evaluation performed by luminescent assay showed most BTZ derivatives have inhibitory effects in micromolar scale. Among them compounds 61, 6t and 6v have the IC50 values of 25.0 mu M, 27.8 mu M and 23.0 mu M, respectively. Moreover 6v is devoid of any inhibitory activity in the assays to other thirteen protein kinases. Besides, SAR is analyzed and a hypothetical enzymatic binding mode is proposed by molecular docking study, which would be useful for new candidates design. (C) 2012 Elsevier Masson SAS. All rights reserved.
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia